The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 2 of the 6 sources its claims cite were checked for support.
Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism
Open accessAbstract
Introduction: Studies comparing levothyroxine (LT4) therapy with LT4 + liothyronine (LT3) or desiccated thyroid extract (DTE) did not detect consistent superiority of either treatment. Here, we investigated these therapies, focusing on the whole group of LT4-treated hypothyroid patients, while also exploring the most symptomatic patients. Methodology: Prospective, randomized, double-blind, crossover study of 75 hypothyroid patients randomly allocated to 1 of 3 treatment arms, LT4, LT4 + LT3, and DTE, for 22 weeks. The primary outcomes were posttreatment scores on the 36-point thyroid symptom questionnaire (TSQ-36), 12-point quality of life general health questionnaire (GHQ-12), the Wechsler memory scale-version IV (VMS-IV), and the Beck Depression Inventory (BDI). Secondary endpoints included treatment preference, biochemical and metabolic parameters, etiology of hypothyroidism, and Thr92Ala-DIO2 gene polymorphism. Analyses were performed with a linear mixed model using subject as a random factor and group as a fixed effect. Results: Serum TSH remained within reference range across all treatment arms. There were no differences for primary and secondary outcomes, except for a minor increase in heart rate caused by DTE. Treatment preference was not different and there were no interferences of the etiology of hypothyroidism or Thr92Ala-DIO2 gene polymorphism in the outcomes. Subgroup analyses of the 1/3 most symptomatic patients on LT4 revealed strong preference for treatment containing T3, which improved performance on TSQ-36, GHQ-12, BDI, and visual memory index (VMS-IV component). Conclusions: As a group, outcomes were similar among hypothyroid patients taking DTE vs LT4 + T3 vs LT4. However, those patients that were most symptomatic on LT4 preferred and responded positively to therapy with LT4 + LT3 or DTE.
Overview
CoChat Summary
## TL;DR
This prospective randomized double-blind crossover trial found no overall differences among levothyroxine (LT4), desiccated thyroid extract (DTE), and LT4+liothyronine in the full sample of 75 hypothyroid patients who completed the study. However, a subgroup analysis suggested that the most symptomatic patients on LT4 improved and preferred therapies containing T3 (DTE or LT4+LT3).
## Key findings
- 75 of 90 enrolled patients completed the study; 15 withdrew before randomization because of relocations and time conflicts.
- In the full cohort, there were no differences among treatments in the primary outcomes: TSQ-36, GHQ-12, BDI, or the 5 WMS-IV subdomains.
- Serum thyroid measures shifted as expected with T3-containing therapies: fasting total T3 was 30% to 50% higher and serum T4 was about 30% lower on DTE or LT4+LT3; the T4/T3 ratio dropped 38% with LT4+LT3 and 56% with DTE.
- In the subgroup analysis, the highest-symptom tercile on LT4 showed significant improvement after switching to LT4+LT3 (P = 0.0005) or DTE (P = 0.0008); the paper says these patients also preferred T3-containing therapy.
## Methods
- Design: Prospective, randomized, double-blind, crossover trial registered at ClinicalTrials.gov NCT02317926.
- Sample: 90 adults with primary hypothyroidism on stable LT4; 75 completed. Participants were mostly Caucasian (77.3%), female (77.3%), average age 50 years, and about 180 pounds.
- Analysis: Mixed-effects models for treatment comparisons; Tukey-adjusted contrasts for between-treatment differences; Plackett-Luce model for treatment preference; subgroup tercile analyses with Kruskal-Wallis, Dunn tests, Holm adjustment, and one-sample exact Wilcoxon tests.
## Limitations
- The paper explicitly states that a significant limitation was that the most notable findings came from a subanalysis not included in the primary outcomes, using a smaller subset and a between-subjects analysis.
- The authors note the study was powered for within-subject differences in TSQ scores, not for the subgroup comparisons, so the subgroup results are less definitive.
- Evident from the text: the subgroup findings may be affected by regression to the mean, which the authors discuss as a possible explanation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
2 Valid · 0 Not valid · 1 Not checked · 35 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This suggests that “responsiveness to therapy containing T3” depends on multiple factors, including genetic background, presence of comorbidities/autoimmune disorders, as well as other yet unidentified biological/environmental factors ( 25 ).”
What the sources say
- Partly supportedcites [25] Ettleson, 2020, Individualized therapy for hypothyroidism: is T4 enough for everyone?, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions report an association between a genetic variant and enhanced response to combination therapy, and recommend screening future trial participants for genetic, autoimmune, and other interfering variables. The paper proposes that individual factors contribute to persistent symptoms on T4, but it does not establish that comorbidities or unidentified environmental factors determine responsiveness to T3-containing therapy. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There is now a consensus that a fraction of the LT4-treated hypothyroid patients with normal serum TSH levels remains symptomatic ( 6 , 7 , 23 , 24 ).”
- Also stated in: § Discussion · plain
“In conclusion, some patients on LT4 therapy remain symptomatic despite normal serum TSH levels.”
What the sources say
- Not checked — no full text of the sourcecites [6] Saravanan, 2002, Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study, Clin Endocrinol (Oxf). source
- Not checked — no full text of the sourcecites [7] Wekking, 2005, Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism, Eur J Endocrinol. source
- Not checked — no full text of the sourcecites [23] Peterson, 2018, An online survey of hypothyroid patients demonstrates prominent dissatisfaction, Thyroid. source
- Supportedcites [24] Peterson, 2016, Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy?, J Clin Endocrinol Metab. source
The Abstract says evidence suggests that a significant proportion of patients treated with LT4 continue to experience residual hypothyroid symptoms, despite treatment at doses that normalize serum TSH. This supports the cited sentence’s claim that some LT4-treated patients with normal TSH remain symptomatic. (LLM, conf=0.90)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonetheless, our findings are clear that no correlation between serum T3 and outcomes could be established in the present investigation, not even in the subanalyses.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the present investigation, the number of these patients was not sufficiently large to affect the outcomes of the whole group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“They also preferred therapy containing T3 or with DTE.”
- Also stated in: § Discussion · hedged
“These patients were also the ones that preferred and benefitted from switching to therapy containing T3, either DTE or LT4 + LT3 combination, suggesting that thyroid hormone signaling in a minority of the patients on LT4 remain subnormal and can be improved (perhaps restored) with therapy containing T3.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Discussion · hedged
9 more claims
Create a free account to see all 38 claims and every source verdict.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“further trials of liothyronine/levothyroxine combination therapy, as well as the use of thyroid extracts, have recently been published, again with negative results. 43,62”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a three-arm, double-blind study of levothyroxine, levothyroxine-liothyronine, and DTE, outcomes were similar for all three treatment groups, although the most symptomatic individuals on levothyroxine at baseline responded to levothyroxine-liothyronine and DTE therapy.192”
From Hypothyroidism (2024) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was no significant difference in Heart Rate, SHBG, TSH, Lipid profile, TSQ-36, and BDI Score.”
From Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of the included studies are insignificant [9, 12–18] except for two studies, one showed a lower TSH, and the other showed a higher TSH [19, 20].”
From Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Almost all these blinded RCTs showed that QoL improved during combined liothyronine/levothyroxine treatment, but that it also improved to the same degree during levothyroxine monotherapy, demonstrating the strong placebo effect of thyroid hormones.”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [43]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 2×
“The BDI is a self-rating scale of 21 items, in which scores of 10 or less indicate normal mood variation and scores of 11 or more reflect increasing levels of depression; clinically important depression is associated with scores of 20 or more (17,18).”
BackgroundMethodScoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 2×
“Several clinical trials addressed the question of whether residual symptoms could be resolved through the use of combination therapy with LT4 and LT3, but evidence of consistent superiority of combination therapy was not obtained (8,9).”
BackgroundResultSelf-citationChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Self-citationSaravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 2×
“The existence of residual symptoms in LT4-treated patients was first documented through a patient survey (5) and later through questionnaires that evaluated thyroid-specific symptoms and quality of life (QoL) (6), as well as sophisticated cognitive tests (7).”
BackgroundL-Thyroxine Therapy in Subclinical Hypothyroidism: A Double-Blind, Placebo-Controlled Trial
COOPER, D. S., HALPERN, R., WOOD, L. C., LEVIN, A. A., & RIDGWAY, E. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-1-18 · Cited by 423 · cited 1×
“Because there are no well-validated and specific instruments to quantify the severity of hypothyroidism, we designed our own TSQ (12,17), a health-related QoL questionnaire, that was modeled after the hypothyroid-specific questionnaires developed by Jaeschke et al (20) and Cooper et al (21).”
MethodAoki, Y., Belin, R. M., Clickner, R., Jeffries, R., Phillips, L., & Mahaffey, K. R. (2007) · Thyroid · doi:10.1089/thy.2006.0235 · Cited by 390
Benson, N., Hulac, D. M., & Kranzler, J. H. (2010) · Psychological Assessment · doi:10.1037/a0017767 · Cited by 309 · cited 9×
“The WMS-IV Beginning of study period 114.7 ± 25.3 76.7 ± 16.3 83.6 ± 19.7 8.78 ± 1.74 End of study period 115.4 ± 25.1 77.3 ± 16.8 84.1 ± 19.6 8.82 ± 1.75 Abbreviations: DTE, desiccated thyroid extract; LT3, liothyronine; LT4, levothyroxine. included 5 subdomains: auditory memory index, visual memory index (VMI), visu…”
BackgroundMethodInfluentialWekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299 · cited 2×
“The existence of residual symptoms in LT4-treated patients was first documented through a patient survey (5) and later through questionnaires that evaluated thyroid-specific symptoms and quality of life (QoL) (6), as well as sophisticated cognitive tests (7).”
BackgroundParadigms of dynamic control of thyroid hormone signaling
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00275 · Cited by 293 · cited 1×
“This apparent conundrum suggests that intracellular T3 levels, which are affected by both serum T3 and locally generated T3, might be playing a role (30).”
BackgroundSelf-citation
Research works printed but not linked: 3
- Roberts, Psychological problems in thyroid disease, Br Thyroid Foundation Newsl., 1996;18:3
- Wechsler, The Wechsler Memory Scalle-IV.
- McDowell, The General Health Questionnaire, Measuring Health. A guide to Rating Scales and Questionnaires.
Cited by
Hashimoto thyroiditis: an evidence-based guide: etiology, diagnosis and treatment
Klubo-Gwiezdzinska, J., & Wartofsky, L. (2022) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16222 · Cited by 207
Primary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Self-citationTaylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Brain Fog in Hypothyroidism: What Is It, How Is It Measured, and What Can Be Done About It
Samuels, M. H., & Bernstein, L. J. (2022) · Thyroid · doi:10.1089/thy.2022.0139 · Cited by 63
“A Netherlands study found no impact of the polymorphism on response to LT4 monotherapy on HRQoL or executive function (58), and another study found no correlation between the Thy92Ala polymorphism and memory (48).”
Metadata
- Authors
- Shakir, M. K. M., Brooks, D. I., McAninch, E. A., Fonseca, T. L., Mai, V. Q., Bianco, A. C., & Hoang, T. D.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Walter Reed National Military Medical Center (US)
- Rush University Medical Center (US)
- University of Chicago (US)
- Corresponding author
- Hoang, Thanh D
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-06-29
- Volume
- 106
- Issue
- 11
- Pages
- e4400-e4413
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8530721
- OpenAlex
- W3174863317
- Cited by
- 92
- References
- 32
- Citations by year
- 2026: 7 · 2025: 25 · 2024: 17 · 2023: 21 · 2022: 16 · 2021: 6
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Walter Reed National Military Medical Center Institutional Research Board
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- hypothyroidism, levothyroxine, desiccated thyroid extract, liothyronine, thyroid hormone replacement, comparative effectiveness, thyroid symptoms, quality of life, depression, memory, heart rate, thyroid-stimulating hormone, treatment preferences
- MeSH terms
- Adult, Aged, Desiccation, Double-Blind Method, Female, Humans, Hypothyroidism, Male, Middle Aged, Placebos, Prospective Studies, Quality of Life, Surveys and Questionnaires, Thyroid Gland, Thyroxine, Tissue Extracts, Triiodothyronine, Treatment Outcome, Cross-Over Studies, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism. https://app.cochat.ai/papers/10.1210/clinem/dgab478
- The paper
- Shakir, M. K. M., Brooks, D. I., McAninch, E. A., Fonseca, T. L., Mai, V. Q., Bianco, A. C., & Hoang, T. D. (2021). Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab478
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.